PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.85
Negative P/E while RVPH shows 19.69. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
2.36
P/B of 2.36 while RVPH has zero book value. Bruce Berkowitz would examine asset quality advantage.
-6.91
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-6.92
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
2.36
Fair value ratio of 2.36 while RVPH has zero value. Bruce Berkowitz would examine valuation methodology.
-13.54%
Negative earnings while RVPH shows yield of 1.27%. Joel Greenblatt would examine path to profitability.
-14.47%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.